PCVX Earnings & Financial Statements
Vaxcyte, Inc.
$68.22
+$3.20(+4.92%)
60
Overall
60
Value
91
Tech
31
Quality
Market Cap
$9.67B
Volume
356.50K
52W Range
$33.62 - $65.00
Target Price
$108.67
PCVX earnings and financial statements: Vaxcyte, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PCVX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$923.67M | -$569.55M | -$468.04M | -$232.26M | -$103.67M |
| EBITDA | -$741.77M | -$448.08M | -$392.10M | -$214.29M | -$96.61M |
| Net income | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -$100.08M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.34M |
| Total liabilities | $317.21M | $205.50M | $167.45M | $52.56M | $40.32M |
| Shareholders’ equity | $2.69B | $3.31B | $1.24B | $953.61M | $284.02M |
| Cash and equivalents | $173.96M | $387.88M | $397.45M | $834.66M | $68.98M |
| Long-term debt | $111.36M | $65.22M | $22.11M | $12.03M | $11.51M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$655.58M | -$452.63M | -$296.79M | -$170.60M | -$121.39M |
| Capital expenditure | -$13.71M | -$22.43M | -$67.88M | -$5.84M | -$6.55M |
| Free cash flow | -$669.29M | -$475.05M | -$312.85M | -$176.44M | -$127.95M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PCVX | $68.22 | +4.9% | 356.50K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |